Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2051 to 2100 of 3030 results for all

  1. InterDry for intertrigo (MIB192)

    NICE has developed a medtech innovation briefing (MIB) on InterDry for intertrigo .

  2. icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)

    NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .

  3. Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I (HTG467)

    Evidence-based recommendations on 2 adjunctive colposcopy technologies (the DYSIS colposcope with DYSISmap and the ZedScan I) for assessing suspected cervical abnormalities in people having colposcopy.

  4. Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (HTG376)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for pulmonary embolism. This involves using ultrasound waves and a drug to break up the clot.

  5. The ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury (HTG356)

    Evidence-based recommendations on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury.

  6. Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)

    Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in adults who have had radioactive iodine.

  7. Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds (MIB11)

    NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds

  8. Get involved

    Tell us what matters to you, your organisation or your community.

  9. Get involved

    Tell us what matters to you, your organisation or your community.

  10. Prioritising our guidance topics

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  11. Micropressure therapy for refractory Ménière's disease (HTG285)

    Evidence-based recommendations on micropressure therapy for refractory Ménière's disease. This involves inserting a grommet (small tube) through the eardrum into the middle ear and blowing air at low pressure into the inner ear.

  12. Intraoperative fluorescence angiography for the evaluation of coronary artery bypass graft patency (HTG60)

    Evidence-based recommendations on intraoperative flourescence angiography in coronary artery bypass grafting. This involves injecting a small amount of a special dye into the blood vessels near to the heart, using a small laser to activitate it and tracking the dye with a video camera.

  13. What is technology appraisal guidance?

    NICE's technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS.

  14. Peripheral nerve-field stimulation for chronic low back pain (HTG309)

    Evidence-based recommendations on peripheral nerve-field stimulation for chronic low back pain. This involves implanting electrodes in the back, connected to a neurostimulator under the skin to mask the back pain by modulating the transmission of pain signals to the brain.

  15. Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia (HTG329)

    Evidence-based recommendations on insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. This involves pulling back the parts of the prostate that are pressing on the urethra so that it's no longer blocked.

  16. Radiofrequency treatment for haemorrhoids (HTG447)

    Evidence-based recommendations on radiofrequency treatment for haemorrhoids in adults. This involves using radiofrequency energy to shrink the haemorrhoids.

  17. Platelet-rich plasma injections for knee osteoarthritis (HTG497)

    Evidence-based recommendations on platelet-rich plasma injections for knee osteoarthritis in adults. This involves taking plasma from a small amount of the person’s own blood and injecting it into the knee.

  18. Bronchial thermoplasty for severe asthma (HTG494)

    Evidence-based recommendations on bronchial thermoplasty for severe asthma in adults. This involves applying heat to the inside walls of the airways.

  19. Superior capsular augmentation for massive rotator cuff tears (HTG477)

    Evidence-based recommendations on superior capsular augmentation for massive rotator cuff tears in adults. This involves using a graft to stabilise the shoulder joint, reduce pain and improve shoulder function.

  20. AlignRT in breast cancer radiotherapy (MIB157)

    NICE has developed a medtech innovation briefing (MIB) on AlignRT in breast cancer radiotherapy .

  21. LiMAx system for assessing the functional capacity of the liver (MIB168)

    NICE has developed a medtech innovation briefing (MIB) on LiMAx system for assessing the functional capacity of the liver .

  22. Patient Status Engine for wireless monitoring of vital signs (MIB271)

    NICE has developed a medtech innovation briefing (MIB) on the Patient Status Engine for wireless monitoring of vital signs .

  23. Lung texture analysis for measuring interstitial lung diseases (MIB272)

    NICE has developed a medtech innovation briefing (MIB) on lung texture analysis for measuring interstitial lung diseases .

  24. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243)

    Evidence-based recommendations on rituximab for the first-line treatment of stage III–IV follicular lymphoma.

  25. Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)

    Evidence-based recommendations on ipilimumab (Yervoy) for previously untreated advanced (unresectable or metastatic) melanoma in adults.

  26. BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis (MIB32)

    NICE has developed a medtech innovation briefing (MIB) on BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis .

  27. OCS Heart system for heart transplant (MIB86)

    NICE has developed a medtech innovation briefing (MIB) on OCS Heart system for heart transplant .

  28. The PolySoft hernia patch used with the ONSTEP technique to treat inguinal hernias (MIB9)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Polysoft hernia patch for use with the ONSTEP technique to treat inguinal hernias

  29. Prevena incision management system for closed surgical incisions (MIB173)

    NICE has developed a medtech innovation briefing (MIB) on Prevena incision management system for closed surgical incisions .

  30. Early value assessment interim statement (PMG39)

    This interim statement outlines early value assessments, a new evidence-based approach designed to improve the care of people and effective use of NHS resources through quicker access to promising health technologies that address national unmet need

  31. Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment (HTG759)

    Late stage assessment (LSA) guidance on bed frames for adults in acute medical or surgical hospital wards.

  32. Sleepio to treat insomnia and insomnia symptoms (HTG624)

    Evidence-based recommendations on Sleepio to treat insomnia and insomnia symptoms.

  33. Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)

    Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.

  34. Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream (ESNM68)

    Summary of the evidence on ivermectin 10 mg/g cream for treating papulopustular rosacea to inform local NHS planning and decision-making

  35. Faricimab for treating diabetic macular oedema (TA799)

    Evidence-based recommendations on faricimab (Vabysmo) for diabetic macular oedema in adults.

  36. Capecitabine for the treatment of advanced gastric cancer (TA191)

    Evidence-based recommendations on capecitabine for treating advanced gastric cancer in adults.

  37. Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)

    Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.

  38. Aflibercept for treating choroidal neovascularisation (TA486)

    Evidence-based recommendations on aflibercept (Eylea) for treating choroidal neovascularisation in adults.

  39. Natalizumab for treating rapidly evolving severe relapsing–remitting multiple sclerosis (TA127)

    Evidence-based recommendations on natalizumab (Tysabri) for treating rapidly evolving severe relapsing–remitting multiple sclerosis in adults.

  40. Artificial intelligence in mammography (MIB242)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence in mammography .

  41. Technology appraisal data: cancer appraisal recommendations

    Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

  42. Consultancy service

    Get expert advice and support from NICE International, part of the UK's National Institute for Health and Care Excellence, for a project in your country

  43. Patient decision aids

    (lung) conditions Asthma inhalers and climate change Show Full list of all PDAs choosing between medical or surgical abortion from 14...

  44. How we support healthtech developers

    With around 2 million healthtech products registered for UK use, differentiating your innovation from the competition is vital. A NICE recommendation helps you cut through the noise, demonstrate your product’s value and smooth your path to market.

  45. NICE Advice service

    NICE Advice - a fee-based advisory service for pharmaceutical and healthtech companies seeking to enter the NHS market,

  46. Pirfenidone for treating idiopathic pulmonary fibrosis (TA504)

    Evidence-based recommendations on pirfenidone (Esbriet) for idiopathic pulmonary fibrosis in adults.

  47. Cabotegravir for preventing HIV-1 in adults and young people (TA1106)

    Evidence-based recommendations on cabotegravir (Apretude) for preventing HIV-1 in adults and young people.

  48. QuikRead go for C-reactive protein testing in primary care (MIB78)

    NICE has developed a medtech innovation briefing (MIB) on the QuikRead go for C-reactive protein testing in primary care

  49. Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction (HTG297)

    Evidence-based recommendations on percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction. This involves implanting a replacement valve with a wire mesh tube called a stent.

  50. Endoscopic injection of bulking agents for gastro-oesophageal reflux disease (HTG28)

    Evidence-based recommendations on endoscopic injection of bulking agents for gastro-oesophageal reflux disease. This involves injecting a filler into the junction using a catheter to make the entry to the stomach narrower, so that the contents of the stomach cannot pass back.